Clozapine, a dibenzodiazepine atypical antipsychotic, demonstrates superior efficacy over all other antipsychotics for treatment-resistant schizophrenia (TRS). The CATIE and other major trials confirmed that approximately 30-60% of patients who failed previous antipsychotic trials achieve clinically meaningful response with clozapine, with effect sizes substantially exceeding switching to other antipsychotics. Beyond positive symptom control, clozapine shows benefits for negative symptoms, reduces suicidality (the only psychotropic medication with this indication), reduces violence and aggression, and decreases substance use comorbidity. Despite this efficacy, clozapine is significantly underutilized worldwide.
Treatment-resistant schizophrenia (TRS) is defined as persistent significant positive symptoms despite at least two adequate antipsychotic trials (different chemical classes, full therapeutic doses, minimum 4-6 weeks each), affecting approximately 30% of patients with schizophrenia. Earlier identification of TRS is associated with better long-term outcomes, with current guidelines recommending consideration of clozapine after failure of two adequate trials rather than multiple sequential trials of other antipsychotics. Risk factors for TRS include early-onset disease, prominent negative symptoms, cognitive impairment, brain structural abnormalities, family history, and certain genetic factors.
Clozapine prescribing requires enrollment in the Risk Evaluation and Mitigation Strategies (REMS) program with mandatory absolute neutrophil count (ANC) monitoring weekly for 6 months, biweekly for next 6 months, then monthly indefinitely, due to risk of severe neutropenia/agranulocytosis (~1% lifetime risk). Beyond hematologic monitoring, comprehensive surveillance includes weight and metabolic parameters (substantial weight gain, dyslipidemia, type 2 diabetes risk), cardiovascular effects (myocarditis, cardiomyopathy, prolonged QTc), seizures (dose-dependent), constipation (potentially fatal ileus, requires aggressive management), sialorrhea, sedation, and metabolic syndrome. Titration begins at 12.5 mg with gradual increase as tolerated to therapeutic dose 300-600 mg/day (some patients require up to 900 mg). Therapeutic drug monitoring helps optimize dosing with target blood level 350-600 ng/mL. Side effect management includes metformin or GLP-1 agonists for weight gain, glycopyrrolate or atropine drops for sialorrhea, and proactive bowel regimen for constipation. Despite these requirements, clozapine remains the most effective option for TRS and should be offered to all eligible patients.